Spots Global Cancer Trial Database for Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

Official Title: Breast Cancer Pathways Impact on Patient Shared Decision Making and Experience in Academic and Community Practice

Study ID: NCT04297384

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Breast Carcinoma

Metastatic Breast Carcinoma

Prognostic Stage IV Breast Cancer AJCC v8

Recurrent Breast Carcinoma

Interventions

Informational Intervention

Quality-of-Life Assessment

Survey Administration

Study Description

Brief Summary: This trial studies the impact of the breast cancer pathways program on the patient experience, including decision making and quality of life. Measuring how the breast cancer pathways program affects decision making and quality of life in patients may help doctors improve cancer education.

Detailed Description: PRIMARY OBJECTIVES: I. Evaluate the impact of breast cancer pathways on patient experience, burden of decision making and quality of life in tertiary cancer center and community oncology practice. II. Identify modifiable factors that affect provider adoption of breast cancer pathways in tertiary cancer center and community oncology practice. OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I: Participants receive standard chemotherapy educational materials. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion. GROUP II: Participants receive personalized information about their cancer, treatment, and side effects. Participants also complete surveys over approximately 22 minutes at the time of first chemotherapy infusion, and approximately 8 weeks after first chemotherapy infusion.